Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.2%

17 terminated/withdrawn out of 129 trials

Success Rate

81.9%

-4.6% vs industry average

Late-Stage Pipeline

5%

6 trials in Phase 3/4

Results Transparency

90%

69 of 77 completed trials have results

Key Signals

21 recruiting69 with results7 terminated10 withdrawn

Enrollment Performance

Analytics

N/A
38(43.2%)
Phase 2
35(39.8%)
Phase 1
8(9.1%)
Phase 3
6(6.8%)
Early Phase 1
1(1.1%)
88Total
N/A(38)
Phase 2(35)
Phase 1(8)
Phase 3(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (129)

Showing 20 of 129 trials
NCT04807816Phase 2Completed

Targeting ATR in Soft-tissue Sarcomas

Role: lead

NCT03784014Phase 3Completed

Molecular Profiling of Advanced Soft-tissue Sarcomas

Role: collaborator

NCT04968106Phase 2Active Not Recruiting

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Role: lead

NCT04095208Phase 2Completed

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Role: lead

NCT06705335Recruiting

Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

Role: lead

NCT07425548Not ApplicableNot Yet Recruiting

Evaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer.

Role: lead

NCT03960021Not ApplicableTerminated

Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin

Role: lead

NCT04912687Not ApplicableCompleted

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

Role: lead

NCT04008238Not ApplicableCompleted

Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

Role: lead

NCT04705818Phase 2Completed

Combining Epigenetic And Immune Therapy to Beat Cancer.

Role: lead

NCT04880382Phase 2Terminated

Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients

Role: lead

NCT04913259Not ApplicableActive Not Recruiting

Remote Monitoring for Ambulatory Care of Elderly Patients With Cancer

Role: lead

NCT02787642Phase 1Completed

A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma

Role: lead

NCT06700057Recruiting

Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

Role: lead

NCT04906187Not ApplicableActive Not Recruiting

Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery

Role: lead

NCT04339218Phase 3Recruiting

Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

Role: lead

NCT02704832Not ApplicableCompleted

Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)

Role: lead

NCT03077178Not ApplicableActive Not Recruiting

Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over

Role: lead

NCT05415527Not ApplicableActive Not Recruiting

Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management

Role: lead

NCT06540846Recruiting

Deep Learning for Histopathological Classification and Prognostication of Gynaecologic Smooth Muscle Tumours

Role: lead